SCHEMBL8669331

SCHEMBL8669331

c1ccc2cc(CCC3CC3)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.51
HRH3 Q9Y5N1 3/20 0.50
CYP1A2 P05177 2/20 0.48
CYP2A6 P11509 1/20 0.48
SIGMAR1 Q99720 1/20 0.47
SLC6A4 P31645 5/20 0.46
ACHE P22303 1/20 0.46
SLC6A2 P23975 4/20 0.45
SLC6A3 Q01959 4/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR7 P34969 1/20 0.45
HTR2B P41595 1/20 0.45
HTR3A P46098 1/20 0.45
HTR4 Q13639 1/20 0.45
KMT2A Q03164 1/20 0.43
KCNH2 Q12809 2/20 0.43
SLC13A5 Q86YT5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8669223 0.93 BCHE (0.59) BCHEHRH3CYP1A2CYP2A6SIGMAR1
SCHEMBL7986820 0.88 SLC6A4 (0.57) HRH3SLC6A4SLC6A2SLC6A3HTR2A
SCHEMBL1581891 0.81 GRIN2D (0.50) HRH3CYP1A2SIGMAR1ACHESLC13A5
SCHEMBL8625212 0.80 CYP1A2 (0.52) HRH3CYP1A2CYP2A6SLC6A4ACHE
SCHEMBL22447157 0.79 ALOX5 (0.37) BCHEHRH3SLC6A4SLC6A2SLC6A3
SCHEMBL6240981 0.79 CYP1A2 (0.65) HRH3CYP1A2CYP2A6SIGMAR1SLC6A4
SCHEMBL29560700 0.79 CYP1A2 (0.65) HRH3CYP1A2CYP2A6SIGMAR1SLC6A4
SCHEMBL6942749 0.78 HRH3 (0.47) HRH3CYP1A2CYP2A6SIGMAR1SLC6A4
SCHEMBL1967603 0.78 NPY5R (0.56) HRH3CYP1A2
SCHEMBL25569484 0.78 SLC6A2 (0.51) HRH3SLC6A4SLC6A2SLC6A3HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5811422-A USEFUL FOR TREATING VIRAL INFECTIONS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-09-22 US disclosed
US-5610294-A VIRAL TREATMENT THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-03-11 US disclosed